Empowered Funds
CHRS icon

Empowered Funds’s Coherus Oncology CHRS Stock Holding History

Empowered Funds’s Portfolio CHRS Stock Details CHRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$212K Buy
+175,000
New +$239K ﹤0.01% 2214

Other funds holding CHRS

TGY2IT
Timothy G. Youngquist 2020 Irrevocable Trust Fort Myers, Florida $530M AUM 95.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Kohlberg Kravis Roberts & Co
Kohlberg Kravis Roberts & Co New York $5.04B AUM 56.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
CM
CM Management Gulf Breeze, Florida $149M AUM 35.54% 1-Year Est. Return
C WorldWide Group
C WorldWide Group Copenhagen, Denmark $3.96B AUM 10.41% 1-Year Est. Return
Hudson Bay Capital Management
Hudson Bay Capital Management Stamford, Connecticut $33B AUM 30.04% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return

Empowered Funds's CHRS Position: Q3 2026 in Review

Empowered Funds opened a new position in Coherus Oncology (CHRS) in Q3 2026: 175,000 shares worth $212K. The stake represents ﹤0.01% of the portfolio and ranks #2214 among its holdings.

100 funds tracked by Wall St. Rank hold CHRS as of Q3 2026.

  • Empowered Funds held 175,000 shares of Coherus Oncology worth $212K as of Q3 2026.
  • Coherus Oncology was a new Empowered Funds position in Q3 2026.
  • Coherus Oncology made up ﹤0.01% of Empowered Funds's portfolio in Q3 2026, its #2214 holding.
  • 100 funds tracked by Wall St. Rank held Coherus Oncology as of Q3 2026.

Based on Empowered Funds's 13F filing for Q3 2026, filed 13 Nov 2026.